# Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy

> **NCT05902247** · PHASE1 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **RADIATION:** Radionuclide Therapy

## Key facts

- **NCT ID:** NCT05902247
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-29
- **Primary completion:** 2025-12-29
- **Final completion:** 2025-12-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902247, "Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05902247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*